Literature DB >> 21874585

Effect of thiazides on bone mineral density in children with idiopathic hypercalciuria.

Víctor García-Nieto1, Margarita Monge-Zamorano, Montserrat González-García, María Isabel Luis-Yanes.   

Abstract

To determine the effect of thiazide treatment on bone mineral density (BMD) in children with idiopathic hypercalciuria (IH) and osteopenia, we reviewed the case notes of 22 children aged 11.7 ± 2.7 years diagnosed with IH and osteopenia who had received thiazides for 2.4 years. The data on this group were compared with those of 32 IH children with osteopenia aged 11.2 ± 2.7 years who had not received thiazide treatment. By the end of the follow-up period, the z-BMD had improved spontaneously in 23 of the 32 control children (72%) and in 12 of the 22 patients on thiazides (54%). Although treated patients had a higher body mass index (BMI) and a higher BMD following treatment, the differences became statistically negligible when these parameters were expressed as z-BMD or as bone mineral apparent density (BMAD). In contrast, within the control group, there were significant differences in BMAD and z-BMD at the end of the follow-up. Patients who had an improved z-BMD at the end of the treatment also showed an increase in their BMI. Based on these results, we conclude that thiazide treatment does not improve the z-BMD in children with IH. More than half of the children suffering from IH enrolled in our study showed a spontaneous improvement in their z-BMD, which was more evident when the initial BMAD was not low and when their BMI increased during the follow-up period.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21874585     DOI: 10.1007/s00467-011-1987-6

Source DB:  PubMed          Journal:  Pediatr Nephrol        ISSN: 0931-041X            Impact factor:   3.714


  46 in total

1.  Bone mineral acquisition in healthy Asian, Hispanic, black, and Caucasian youth: a longitudinal study.

Authors:  L K Bachrach; T Hastie; M C Wang; B Narasimhan; R Marcus
Journal:  J Clin Endocrinol Metab       Date:  1999-12       Impact factor: 5.958

2.  Weight gain reverses bone turnover and restores circadian variation of bone resorption in anorexic patients.

Authors:  A Caillot-Augusseau; M H Lafage-Proust; P Margaillan; N Vergely; S Faure; S Paillet; F Lang; C Alexandre; B Estour
Journal:  Clin Endocrinol (Oxf)       Date:  2000-01       Impact factor: 3.478

3.  Bone mineral density in pediatric patients with idiopathic hypercalciuria.

Authors:  V García-Nieto; C Ferrández; M Monge; M de Sequera; M D Rodrigo
Journal:  Pediatr Nephrol       Date:  1997-10       Impact factor: 3.714

4.  New approaches for interpreting projected bone densitometry data.

Authors:  D R Carter; M L Bouxsein; R Marcus
Journal:  J Bone Miner Res       Date:  1992-02       Impact factor: 6.741

5.  Sodium transport and bone mineral density in hypercalciuria with thiazide treatment.

Authors:  G S Reusz; M Dobos; B Vásárhelyi; P Sallay; A Szabó; C Horváth; A Szabó; D J Byrd; H H Thole; T Tulassay
Journal:  Pediatr Nephrol       Date:  1998-01       Impact factor: 3.714

6.  Bone alterations in children with idiopathic hypercalciuria at the time of diagnosis.

Authors:  Maria-Goretti Moreira Guimarães Penido; Eleonora Moreira Lima; Viviane Santuari Parizotto Marino; Ana-Luiza Fialho Tupinambá; Anderson França; Marcelo Ferraz Oliveira Souto
Journal:  Pediatr Nephrol       Date:  2002-12-19       Impact factor: 3.714

7.  Reduced bone mass in children with idiopathic hypercalciuria and in their asymptomatic mothers.

Authors:  Michael Freundlich; Evelyn Alonzo; Ezequiel Bellorin-Font; Jose R Weisinger
Journal:  Nephrol Dial Transplant       Date:  2002-08       Impact factor: 5.992

Review 8.  Idiopathic hypercalciuria in children--how valid are the existing diagnostic criteria?

Authors:  Lavjay Butani; Alok Kalia
Journal:  Pediatr Nephrol       Date:  2004-03-31       Impact factor: 3.714

9.  Prevention of calcium nephrolithiasis with low-dose thiazide, amiloride and allopurinol.

Authors:  G Maschio; N Tessitore; A D'Angelo; A Fabris; F Pagano; A Tasca; G Graziani; A Aroldi; M Surian; G Colussi; A Mandressi; A Trinchieri; F Rocco; C Ponticelli; L Minetti
Journal:  Am J Med       Date:  1981-10       Impact factor: 4.965

10.  Thiazide diuretics directly induce osteoblast differentiation and mineralized nodule formation by interacting with a sodium chloride co-transporter in bone.

Authors:  Melita M Dvorak; Cyrille De Joussineau; D Howard Carter; Trairak Pisitkun; Mark A Knepper; Gerardo Gamba; Paul J Kemp; Daniela Riccardi
Journal:  J Am Soc Nephrol       Date:  2007-07-26       Impact factor: 10.121

View more
  4 in total

1.  Does thiazide treatment improve bone mineral density in hypercalciuric children?

Authors:  Maria Goretti Moreira Guimarães Penido; Marcelo de Sousa Tavares
Journal:  Pediatr Nephrol       Date:  2012-04-13       Impact factor: 3.714

2.  Response to: A role for thiazide diuretic therapy in preventing bone loss, fracture and nephrolithiasis in individuals with thalassemia and hypercalciuria?

Authors:  A D Dede; G Trovas; E Chronopoulos; I K Triantafyllopoulos; I Dontas; N Papaioannou; S Tournis
Journal:  Osteoporos Int       Date:  2017-02-13       Impact factor: 4.507

Review 3.  Idiopathic hypercalciuria and bone health.

Authors:  Laura E Ryan; Steven W Ing
Journal:  Curr Osteoporos Rep       Date:  2012-12       Impact factor: 5.096

4.  Evolution of bone mineral density in patients with idiopathic hypercalciuria: a 20-year longitudinal study.

Authors:  German Perez-Suarez; Ma Isabel Luis Yanes; Maria Cecilia Martín Fernández de Basoa; Elena Sánchez Almeida; Víctor M García Nieto
Journal:  Pediatr Nephrol       Date:  2020-09-26       Impact factor: 3.714

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.